Shots: The EC’s approval is based on data from DELIVER and REFINE studies evaluating the efficacy, PK, and PD of Tysabri (300mg, SC, q4w) vs Tysabri (300mg, IV, q4w) in […]readmore
Tags : SC
Shots: The Health Canada has approved Darzalex SC (daratumumab) in four regimens across five indications in patients with MM, notably newly diagnosed, transplant-ineligible patients as well as relapsed/refractory patients The […]readmore
Shots: The P-III FeDeriCa study involves assessing of SC inj. of Perjeta + Herceptin + CT vs IV infusion of Perjeta + Herceptin + CT in 500 patients with HER2+ […]readmore
Shots: The P-III FeDeriCa study involves assessing of Perjeta (pertuzumab) and Herceptin (trastuzumab) as FDC in SC formulation + CT (IV) vs its standard IV Infusion formulation + CT in […]readmore
Shots: The NDA filing is based on P-III VISIBLE 1 study results assessing Vedolizumab (SC, 108mg, q2w) as maintenance therapy vs PBO in 216 patients with mod. to sev. active […]readmore
Shots: The approval of Xembify reflects Grifols’ commitment to R+D+i and innovation which enables the company to develop new therapies and enhances its Bioscience Division’s product portfolio Grifol is working with […]readmore
Shots: The BLA application is based on P-III VISIBLE 1 study results assessing vedolizumab (SC,108mg) as maintenance therapy vs PBO in 216 patients with moderate to severely active UC achieving […]readmore
Shots: The P-III COLUMBA (NCT03277105) study involves assessing of Darzalex (SC) + recombinant human hyaluronidase PH20 (2000 U/mL) vs Darzalex (IV) in 522 patients with r/r multiple myeloma The P-III […]readmore